{
    "root": "311ae682-1c49-44e0-e063-6394a90a5184",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "bupropion",
    "value": "20250324",
    "ingredients": [
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "bupropion hydrochloride extended-release ( sr ) tablets indicated treatment major depressive disorder ( mdd ) , defined diagnostic statistical manual ( dsm ) . efficacy bupropion treatment major depressive episode established two 4-week controlled inpatient trials one 6-week controlled outpatient trial adult subjects mdd [ ( 14 ) ] . efficacy bupropion hydrochloride extended-release ( sr ) tablets maintaining antidepressant response 44 weeks following 8 weeks acute treatment demonstrated placebo-controlled trial [ ( 14 ) ] .",
    "contraindications": "starting dose : 150 mg/day . ( 2.1 ) general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) 3 days , may increase dose 300 mg/day , given 150 mg twice daily interval least 8 hours . ( 2.1 ) usual target dose : 300 mg/day 150 mg twice daily . ( 2.1 ) maximum dose : 400 mg/day , given 200 mg twice daily , patients responding 300 mg/day . ( 2.1 ) periodically reassess dose need maintenance treatment . ( 2.1 ) moderate severe hepatic impairment : 100 mg daily 150 mg every day . ( 2.2 , 8.7 ) mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets usp ( sr ) , 100 mg bupropion hydrochloride , blue , round , biconvex , film-coated tablets debossed \u201c \u201d one side \u201c 522 \u201d . ndc : 70518-2641-00 ndc : 70518-2641-01 packaging : 30 1 blister pack packaging : 30 1 blister pack store room temperature , 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients seizure disorder . bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated immediate-release formulation bupropion [ ( 5.3 ) ] . bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) , ( 7.3 ) ] . maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release ( sr ) tablets within 14 days discontinuing treatment bupropion hydrochloride extended-release ( sr ) tablets contraindicated . increased risk hypertensive bupropion hydrochloride extended-release ( sr ) tablets used concomitantly maois . bupropion hydrochloride extended-release ( sr ) tablets within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release ( sr ) tablets patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.4 , 2.5 ) , ( 5.4 ) , ( 7.6 ) ] . bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release ( sr ) tablets . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride extended-release (SR) tablets are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).\n                  The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .\n\n \n                  The efficacy of bupropion hydrochloride extended-release (SR) tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .",
    "contraindications_original": "Starting dose: 150 mg/day. ( 2.1 ) General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. ( 2.1 ) Usual target dose: 300 mg/day as 150 mg twice daily. ( 2.1 ) Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. ( 2.1 ) Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. ( 2.2 , 8.7 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride extended-release tablets USP (SR), 100 mg of bupropion hydrochloride, are blue, round, biconvex, film-coated tablets debossed with \u201cS\u201d on one side and \u201c522\u201d on the other.\n                  NDC: 70518-2641-00\n                  NDC: 70518-2641-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a seizure disorder.\n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate-release formulation of bupropion\n  \n   [see\n   \n    Warnings and Precautions (5.3)]\n  \n   .\n \n  \n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7.3)]\n  \n   .\n \n  \n                     The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release (SR) tablets or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release (SR) tablets is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release (SR) tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release (SR) tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release (SR) tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated\n  \n   [see\n   \n    Dosage and Administration (2.4,\n   \n    2.5),\n  \n   \n                        \n                           Warnings and Precautions (5.4)\n                        \n                        ,\n   \n    Drug Interactions (7.6)].\n  \n   \n                     \n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release (SR) tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported\n  \n   [see\n   \n    Warnings and Precautions (5.8)]\n  \n   ."
}